Series A Funded Biotechnology Startups
The ten most recent Series A rounds in biotechnology and pharmaceuticals span September through November 2025, with companies operating across the United S…
The ten most recent Series A rounds in biotechnology and pharmaceuticals span September through November 2025, with companies operating across the United States, China, France, and Portugal. Disclosed amounts range from $5M for AltrixBio in Cambridge to $122M for Adcytherix in Marseille, with Ollin Biosciences in Austin also clearing nine figures at $100M. Three rounds — Norn Gene (Chengdu), Mondego Bio (Cantanhede), and RabPharma (Guangdong) — closed without public disclosure of the amount raised.
Geographically, the US accounts for four of the ten companies shown, distributed across Cambridge, San Francisco, La Jolla, and Austin rather than concentrated in a single hub. Marseille is the most repeated city in the dataset: Adcytherix and Tafalgie Therapeutics both closed Series A rounds there within a month of each other in late September and mid-October 2025. China contributes three entries across Shanghai, Chengdu, and Guangdong, while Portugal's Mondego Bio represents a less common geography for Series A biotech capital at this stage.
Most recent rounds
10 shownRelated listings
Frequently asked
What are the largest disclosed Series A rounds in biotech and pharma recently?
Adcytherix in Marseille leads the disclosed rounds at $122M, followed by Ollin Biosciences in Austin at $100M. The next tier is considerably smaller: Brise Pharma (Shanghai) at $28M and Bexorg (San Francisco) at $23M.
How many recent biotech Series A rounds did not disclose their raise amount?
Three of the ten most recent rounds closed without a public amount: Norn Gene (Chengdu), Mondego Bio (Cantanhede, Portugal), and RabPharma (Guangdong). All three are based outside the United States.
Which cities appear most frequently among recent biotech and pharma Series A raises?
Marseille is the only city with two entries in this view — Adcytherix ($122M, October 2025) and Tafalgie Therapeutics ($14M, September 2025). US companies are spread across four separate cities: Cambridge, San Francisco, La Jolla, and Austin, with no single hub dominating.
How active is China in Series A biotech fundraising right now?
Three of the ten most recent rounds originate from Chinese cities — Brise Pharma (Shanghai, $28M), Norn Gene (Chengdu, undisclosed), and RabPharma (Guangdong, undisclosed). The two undisclosed amounts make direct size comparison difficult, but Chinese deal flow is spread across distinct regional markets rather than concentrated in one city.
What does the range of disclosed round sizes look like for Series A biotech deals?
Among the seven rounds with disclosed amounts, sizes span from $5M (AltrixBio, Cambridge) to $122M (Adcytherix, Marseille). Four of those seven disclosed rounds fall between $14M and $28M, while two clear $100M — suggesting the distribution has a distinct upper tail rather than clustering around a single median.
How recent is the Series A activity visible in this segment?
All ten rounds closed between September 12 and November 10, 2025, a span of roughly two months. The two most recent entries — Brise Pharma and Norn Gene — both closed in the first two weeks of November 2025.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.